SOURCE: Peregrine Pharmaceuticals

Peregrine Pharmaceuticals

September 01, 2011 08:00 ET

Peregrine to Present at Stifel Nicolaus Healthcare Conference September 8, 2011 at 11:30 AM EDT

TUSTIN, CA--(Marketwire - Sep 1, 2011) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced it will present at the 2011 Stifel Nicolaus Healthcare Conference in Boston, Massachusetts on Thursday, September 8, 2011 at 11:30 AM EDT.

Peregrine's presentation will be webcast live and available for replay until September 22, 2011 at: http://ir.peregrineinc.com/events.cfm

For more information about this conference, please visit: http://www.tweisel.com/Stifel/ConferencesAndEvents/

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Contact Information